[Mexican clinical experience in ocular anti-angiogenic therapy].
Retinal pathological angiogenesis is the leading cause of visual loss in a wide variety of ocular diseases. Some of the examples include: Age-related macular degeneration, diabetic retinopathy and retinopathy associated with prematurity. These last two entities are, in addition, public health problems in developing countries. Recent physiopathological studies, have demonstrated that growth factors play a key role on angiogenesis. Anti-angiogenic therapy came about as an attempt to inhibit the action of growth factors over the process of pathological angiogenesis in order to preserve vision. The objective of this review is to describe Mexico's experience using this therapeutic approach.
Quiroz-Mercado
Hugo
H
Servicio de Retina, Asociación para Evitar la Ceguera en México IAP, México D.F., México. hugoquiroz@yahoo.com
Vélez-Montoya
Raúl
R
Fromow-Guerra
Jans
J
Guerrero-Naranjo
José Luis
JL
Moreno-Páramo
Daniel
D
Morales-Cantón
Virgilio
V
D000465:Algorithms; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D006801:Humans; D008800:Mexico; D015861:Retinal Neovascularization / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab